Charles Schwab
SLDB icon

Charles Schwab’s Solid Biosciences SLDB Stock Holding History

Charles Schwab’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.44M Buy
244,401
+83,671
+52% +$634K ﹤0.01% 2723
2026
Q1 		$1.16M Sell
160,730
-807
-0.5% -$5.18K ﹤0.01% 2860
2025
Q4 		$911K Sell
161,537
-522
-0.3% -$2.83K ﹤0.01% 2951
2025
Q3 		$1,000K Sell
162,059
-49,015
-23% -$287K ﹤0.01% 2955
2025
Q2 		$1.03M Buy
211,074
+142,467
+208% +$504K ﹤0.01% 2891
2025
Q1 		$254K Buy
68,607
+5,220
+8% +$22.3K ﹤0.01% 3231
2024
Q4 		$254K Hold
63,387
– – ﹤0.01% 3291
2024
Q3 		$442K Hold
63,387
– – ﹤0.01% 3193
2024
Q2 		$359K Buy
63,387
+53,111
+517% +$476K ﹤0.01% 3319
2024
Q1 		$137K Buy
+10,276
New +$96.2K ﹤0.01% 3280
2023
Q2 		– Sell
-10,000
Closed -$47.4K – 3676
2023
Q1 		$47.4K Buy
+10,000
New +$60.1K ﹤0.01% 3355
2022
Q2 		– Sell
-8,427
Closed -$152K – 3632
2022
Q1 		$152K Sell
8,427
-1,635
-16% -$28.9K ﹤0.01% 3350
2021
Q4 		$265K Hold
10,062
– – ﹤0.01% 3308
2021
Q3 		$361K Hold
10,062
– – ﹤0.01% 3224
2021
Q2 		$553K Buy
10,062
+5,283
+111% +$349K ﹤0.01% 3135
2021
Q1 		$397K Buy
4,779
+863
+22% +$95.5K ﹤0.01% 3158
2020
Q4 		$446K Buy
3,916
+364
+10% +$23K ﹤0.01% 3029
2020
Q3 		$109K Sell
3,552
-3,635
-51% -$139K ﹤0.01% 3247
2020
Q2 		$316K Buy
7,187
+1,242
+21% +$51.6K ﹤0.01% 3020
2020
Q1 		$214K Buy
5,945
+84
+1% +$4.16K ﹤0.01% 2998
2019
Q4 		$392K Sell
5,861
-388
-6% -$42.8K ﹤0.01% 2908
2019
Q3 		$970K Buy
6,249
+393
+7% +$44.5K ﹤0.01% 2580
2019
Q2 		$506K Buy
5,856
+1,541
+36% +$168K ﹤0.01% 2807
2019
Q1 		$596K Sell
4,315
-485
-10% -$122K ﹤0.01% 2698
2018
Q4 		$1.93M Sell
4,800
-127
-3% -$59.7K ﹤0.01% 2346
2018
Q3 		$3.49M Buy
4,927
+2,393
+94% +$1.5M ﹤0.01% 2231
2018
Q2 		$1.35M Buy
2,534
+177
+8% +$54.5K ﹤0.01% 2491
2018
Q1 		$266K Buy
+2,357
New +$796K ﹤0.01% 2911

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Charles Schwab's SLDB Position: Q2 2026 in Review

Charles Schwab increased its Solid Biosciences (SLDB) stake by 52% in Q2 2026, buying an estimated $634K and bringing the position to 244,401 shares worth $2.44M. The position accounts for ﹤0.01% of the portfolio, ranked #2723.

Charles Schwab first reported a position in SLDB in Q1 2018 and has held it in 28 quarters since. The position peaked at $3.49M in Q3 2018. 156 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

  • Charles Schwab held 244,401 shares of Solid Biosciences worth $2.44M as of Q2 2026.
  • Charles Schwab bought 83,671 Solid Biosciences shares in Q2 2026, an estimated $634K.
  • Solid Biosciences made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2723 holding.
  • Charles Schwab first reported a position in Solid Biosciences in Q1 2018 and has held it in 28 quarters since.
  • Charles Schwab's Solid Biosciences position peaked at $3.49M in Q3 2018.
  • 156 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.